Open AccessLow-dose (7.5 mg/kg) bevacizumab may be a viable option in recurrent ovarian cancer: A retrospective study
Author(s) -
Aykut Demirkıran,
MelekKarakurt Eryilmaz,
Mustafa Karaağaç,
Murat Araz,
Mustafa Korkmaz,
Mehmet Zahid Koçak,
Mehmet Artaç
Publication year - 2022
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_1879_20
Subject(s) - medicine , bevacizumab , carboplatin , gemcitabine , oncology , ovarian cancer , retrospective cohort study , paclitaxel , chemotherapy , gastroenterology , surgery , cancer , cisplatin
Bevacizumab (BEV) is a humanized monoclonal antibody of vascular endothelial growth factor receptors and, as a result of clinical trials, was approved for the treatment of recurrent ovarian cancer (ROC). The aim of this study was to assess the clinical utility of BEV in patients with ROC in real-world practice beyond clinical trials.